Biotech news
Americas
Human embryos whose genomes have been edited should not be used to create a pregnancy until it is certain that changes can be made without introducing undesired changes, according to a new report by an influential panel. 10 September 2020
Americas
A US Department of Health and Human Services agency will investigate whether Moderna disclosed information on government funding in patent applications relating to its COVID-19 vaccine. 8 September 2020
Biotech
Biologics are playing an increasingly important role in healthcare, but for corporate patent counsel, the differences in rules between the US and Europe are a real cause for concern. 4 September 2020
Americas
California-based molecular diagnostics company CareDx and Stanford University have dropped their patent infringement suit against Tai Diagnostics, nearly five months after filing the complaint. 3 September 2020
Asia
As AI becomes a crucial weapon in the battle against the global pandemic, companies in the field need to ensure that their valuable IP is protected, as Mao Xiao Hong and Danny Yap of IPOS International explain. 1 September 2020
Biotech
In an LSPN Connect session, Millipore’s senior corporate patent counsel, Ben Sodey, and head of legal and IP at Arbor, Kelly Morgan, shared their insights on the latest developments in this area of gene editing technology. 21 August 2020
Americas
Johnson & Johnson is set to buy biotech Massachusetts-based Momenta Pharmaceuticals for $6.5 billion, in a move aimed at strengthening its portfolio of autoimmune disease treatments. 20 August 2020
Americas
McDermott Will & Emery has strengthened its IP practice in Boston with the addition of Michael Siekman and Jenny Chen as partners. 12 August 2020
Pharma
US biotechnology company Novavax has signed a deal with Takeda Pharmaceuticals to develop, manufacture and market a COVID-19 vaccine in Japan, it was announced on Friday, August 7. 10 August 2020
Biotech
With any rapidly-developing field, particularly the life sciences, the importance of a coherent IP strategy cannot be ignored. 6 August 2020